An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Study summary

The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also provide another mechanism for reporting adverse events related to study drug safety.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedRuxolitinib and Capecitabine

Plus 1 other study approaches.

Who it may be forPancreatic Cancer · Colorectal Cancer (CRC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 17, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 2

Interventional

Where is it offered?9 U.S. locations

Locations may change over time.

Who runs it?Incyte Corporation

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Incyte Corporation
Interventions being studied: Drug: Ruxolitinib; Drug: Capecitabine; Drug: Regorafenib

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated.
Currently tolerating treatment in the parent protocol.
Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator.
Have at least stable disease, as determined by the investigator.
Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.

Reasons someone may not be able to joinExclusion criteria

Has been permanently discontinued from study treatment in the parent study for any reason.
Able to access ruxolitinib and/or background cancer therapy outside of the clinical study.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

UCLA Healthcare Hematology-OncologySanta Monica, California
University of LouisvilleLouisville, Kentucky
New York Oncology Hematology Pc.Clifton Park, New York
Tennessee OncologyNashville, Tennessee
University of Texas M. D. Anderson Cancer CenterHouston, Texas
Renovatio Clinical Consultants LlcThe Woodlands, Texas
Sp Zoz Szpital Uniwersytecki W Krakowie Oddzial Kliniczny HematologiiKrakow
Samodzielny Publiczny Szpital KlinicznyLublin
Instytut Hematologii I TransfuzjologiiWarsaw

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 17, 2026. Always confirm current availability with the study team.

View original record ↗